Induction outcomes in adult kidney transplantation: Two decades of UNOS data analysis
Transplant Immunology · 2025-03 · 89 · 102198
DOI: 10.1016/j.trim.2025.102198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Immunology, 2025-03. Verfasst von Emmanuel Aydin-Ghormoz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology and Hypertension, Albany Medical Center, Albany, NY, United States of America. Electronic address: ayd…. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Immunosuppressive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: National Science Foundation.
Abstract (Originalsprache)
OBJECTIVES: In the US, 92 % of kidney transplant recipients are treated with induction therapy. This analysis assesses the impact of induction immunosuppression on outcomes such as graft failure, patient mortality, and length of hospitalization. MATERIAL AND METHODS: Retrospective analysis of the UNOS database in adults who received a kidney transplant from January 2000 to June 2022. Analysis focused on induction regimens including anti-thymocyte globulin (ATG), alemtuzumab and basiliximab with maintenance immunosuppression of calcineurin inhibitors, mycophenolate with or without prednisone. Multivariable logistic regression was performed to identify factors correlating with outcomes. Kaplan-Meier product limit method assessed survival. RESULTS: Alemtuzumab correlated with increased graft failure in deceased-donor and living-donor kidney transplants (HR 1.075 [1.015-1.138] p = 0.013 and HR 1.096 [1.011-1.188] p = 0.026 respectively) and with increased mortality in living-donor kidney transplants (HR 1.215 [1.107-1.332] p < 0.001). Steroids maintenance was associated with fewer acute rejections in both deceased-donor and living-donor kidney transplants (HR = 0.875 [0.84-0.90] p < 0.001 and HR = 0.88 [0.83-0.93] p < 0.001 respectively). Odds of CMV was lower with alemtuzumab. Induction with alemtuzumab was associated with shorter length of stay in both deceased-donor and living-donor kidney transplants and longer time to first hospitalization in living-donor kidney transplants compared to ATG. CONCLUSIONS: Alemtuzumab correlated with shorter length of stay, fewer re-hospitalizations and less CMV infections. However, it was associated with higher odds of graft failure and mortality in adult kidney transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Nephrology and Hypertension, Albany Medical Center, Albany, NY, United States of America. Electronic address: aydinge@amc.edu.
- Department of General Surgery, Garnet Health Medical Center, Middletown, NY, United States of America.
- College of Medicine and Life Sciences, University of Toledo, Toledo, OH, United States of America.
- Schar School of Policy and Government, George Mason University, Arlington, VA, United States of America.
- Department of Medicine, Division of Nephrology and Hypertension, Albany Medical Center, Albany, NY, United States of America.
Förderung
- National Science Foundation
Zitieren
APA
Aydin-Ghormoz, E., Ortiz, J., Schubauer, K., Koizumi, N., Li, M. H., & Faddoul, G. (2025). Induction outcomes in adult kidney transplantation: Two decades of UNOS data analysis. Transplant Immunology, 89, 102198. https://doi.org/10.1016/j.trim.2025.102198
Vancouver
Aydin-Ghormoz E, Ortiz J, Schubauer K, Koizumi N, Li MH, Faddoul G. Induction outcomes in adult kidney transplantation: Two decades of UNOS data analysis. Transplant Immunology. 2025;89:102198. doi:10.1016/j.trim.2025.102198
BibTeX
@article{AydinGhormoz2025,
author = {Aydin-Ghormoz, Emmanuel and Ortiz, Jorge and Schubauer, Kathryn and Koizumi, Naoru and Li, Meng-Hao and Faddoul, Geovani},
title = {Induction outcomes in adult kidney transplantation: Two decades of UNOS data analysis},
journal = {Transplant Immunology},
year = {2025},
volume = {89},
pages = {102198},
doi = {10.1016/j.trim.2025.102198}
}
EUVIMED